Oral semaglutide is now available in the US — here's what that actually means

If you've been taking injectable semaglutide — or have been thinking about starting a GLP-1 — you've probably heard that it now comes in a pill. Maybe your pharmacy mentioned it. Maybe someone in your support group switched. Maybe you're wondering whether you can skip the injections entirely.

The short answer: it depends on which pill, what you're treating, and some important realities about how oral semaglutide behaves in the body compared to the shot.

There are actually two separate products here, approved for different conditions, with different dose structures and different evidence behind them. Getting those distinctions right matters before you bring this topic to your clinician.

Here's what you need to know.

• There are two FDA-approved oral semaglutide products in the US — Ozempic pill (for type 2 diabetes) and Wegovy pill (for weight loss). They are different products with different doses and indications.
• Both use the same molecule as the injections, but oral bioavailability is roughly 1–2%, compared to 89% for the shot. The pills compensate with much higher doses.
• In the Phase III OASIS 4 trial, the Wegovy pill produced an average weight loss of 16.6% at 64 weeks among participants who took it as directed — with no published head-to-head comparison to the injectable.
• Taking oral semaglutide correctly requires a specific morning routine: empty stomach, up to 4 oz of plain water only, then at least 30 minutes before eating, drinking anything else, or taking other medications. Missing this window reduces absorption.

Semaglutide — the active ingredient in both Ozempic and Wegovy injections — is now available in pill form under those same brand names. But these are not interchangeable products, and neither is interchangeable with the injections.

Ozempic pill (semaglutide tablets 1.5 mg, 4 mg, and 9 mg) became available in US pharmacies on May 4, 2026, for adults with type 2 diabetes. It is a reformulation and rebranding of Rybelsus — the original oral semaglutide approved in 2019. The doses differ from Rybelsus (which came in 3 mg, 7 mg, and 14 mg), but the efficacy and safety profile are equivalent. If you are currently on Rybelsus, your clinician will guide your transition.

Wegovy pill (semaglutide tablets 25 mg) was FDA-approved on December 22, 2025, and launched in the US in January 2026. It is approved for chronic weight management in adults with obesity, or in adults with overweight who have at least one weight-related health condition. It carries the same cardiovascular risk reduction indication as Wegovy injection for adults with established cardiovascular disease.

The names are shared with the injections by design — Novo Nordisk made that choice to signal familiarity. It's worth being aware of, because a prescription for ""Wegovy"" in 2026 could mean the pill or the shot, and those are not the same thing.

Ozempic pill is for adults with type 2 diabetes: improving blood sugar control, and reducing the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) in those who also have known heart disease or are at high cardiovascular risk. It is the only oral GLP-1 approved for both primary and secondary cardiovascular risk reduction in type 2 diabetes.

Wegovy pill is for adults with obesity (BMI ≥30) or overweight (BMI ≥27 with at least one weight-related condition). It is also approved to reduce cardiovascular risk in adults with established heart disease and obesity or overweight.

A distinction that matters: Wegovy tablets have not been studied or approved for weight reduction in adults with type 2 diabetes. The Phase III trial that led to approval excluded people with diabetes. The FDA label makes this explicit — and notes that semaglutide concentrations from the tablet are lower and more variable in people with T2DM, which may affect how well it works in that population.

If you have type 2 diabetes and a weight loss goal, which product is right for you — and whether the pill or the injection is the better route — is a question for your clinician, not a decision to make based on what's covered by insurance or what's easier to pick up.

The semaglutide molecule is identical. What changes is how it gets into your bloodstream.

Injectable semaglutide has a bioavailability of around 89% — meaning nearly all of the injected dose reaches your circulation. The pill relies on an absorption enhancer called SNAC (salcaprozate sodium) that helps carry semaglutide through the stomach lining. Even with this, bioavailability is approximately 1–2%.

The pills are dosed much higher to account for this gap. In people without type 2 diabetes, the FDA label notes that average steady-state semaglutide concentrations from the 25 mg Wegovy tablet are predicted to be comparable to the 2.4 mg weekly injection — but with greater variability. Where most people on the injection land in a fairly consistent concentration range, people on the pill can land across a wider spread.

In people with type 2 diabetes, concentrations from the 25 mg tablet are lower on average than from the injection. The label notes that some people with T2DM may experience subtherapeutic concentrations, and that switching to the injection may be appropriate if response is inadequate.

Because absorption happens primarily in the stomach and depends on specific conditions, taking the pill correctly matters more than it does with most medications. Per the FDA label: take one tablet on an empty stomach each morning with up to 4 oz of plain water. No other liquids. After taking it, wait at least 30 minutes before eating, drinking anything else, or taking other oral medications. Swallow the tablet whole — do not split, crush, or chew it.

For some people this routine fits naturally. For others — those taking levothyroxine, multiple morning medications, or who eat early — it adds real complexity. There is also a drug interaction worth knowing: in a clinical study, taking the Wegovy tablet alongside levothyroxine increased levothyroxine exposure by 33%. If you take thyroid medication, that is a specific conversation to have with your clinician before starting.

The FDA approval of the Wegovy pill was based on the Phase III OASIS 4 trial (NCT05564117), published in The New England Journal of Medicine in September 2025.

The trial enrolled 307 adults with obesity or overweight and at least one weight-related comorbidity, excluding people with diabetes. Participants were randomized 2:1 to once-daily oral semaglutide 25 mg or placebo, with a 12-week dose escalation phase followed by 52 weeks at the 25 mg maintenance dose.

Among participants who followed the treatment as directed:

• Average weight loss was 16.6% at 64 weeks, compared to 2.7% with placebo
• 34.4% reached at least 20% weight loss, versus 2.9% on placebo

In the treatment-policy analysis — which counted all randomized participants regardless of whether they stayed on medication — average weight loss was 13.6% versus 2.2% for placebo.

Serious adverse events were less common with oral semaglutide (3.9%) than with placebo (8.8%). The most common side effects were gastrointestinal: nausea, vomiting, diarrhea, and constipation — the same pattern seen with injectable semaglutide, most frequent during dose escalation.

There is no published head-to-head trial comparing the Wegovy pill directly to the 2.4 mg injectable Wegovy at a similar timeframe. The figures above reflect what the pill achieved in OASIS 4 on its own terms.

The pill formulation is newer, and some questions will take time to answer.

Long-term data beyond 64 weeks is limited for these dose levels. The injectable Wegovy's long-term profile was established through larger, longer trials — the STEP program — that the pill doesn't yet match in depth.

Real-world adherence data doesn't exist yet for the pill formulations. Clinical trials tend to attract participants who are motivated and supported. Whether the morning fasting routine holds up in daily life, at scale, will take time to see.

How the pill performs in people who take proton pump inhibitors, have gastric conditions, or have had bariatric surgery isn't fully characterized in the available data.

And as noted, the greater variability in blood concentrations from the tablet means some people may respond differently than the trial averages suggest.

• Am I a candidate for the pill, or does my situation make the injection the better starting point?
• If I have type 2 diabetes, which oral semaglutide product fits my goals — and how do we monitor whether it's working?
• How does the morning fasting window interact with my other medications, particularly levothyroxine or anything else I take before breakfast?
• If I switch from the injection to the pill, what would prompt us to switch back?
• What results should I expect to see in the first 12 weeks, and what would be a reason to reassess?

• Whether you're consistently hitting the fasting-and-wait routine each morning
• GI side effects — nausea and vomiting are most common during dose escalation; note how severe they are and how long they last
• Weight at weeks 4, 8, and 12 — some variability is expected as the dose escalates through 1.5 mg, 4 mg, and 9 mg to 25 mg
• If you have diabetes: fasting glucose and any hypoglycemia symptoms, especially if you're also on insulin or a sulfonylurea
• Effects on other oral medications — semaglutide slows gastric emptying, which can influence how other drugs are absorbed

Oral semaglutide is a real addition to what's available for people managing weight or type 2 diabetes. The OASIS 4 data is solid, and having a pill option matters — particularly for people who prefer not to inject, or for whom the injections aren't working within their routine.

But it's not simply ""Wegovy without the needle."" The two forms behave differently in the body, are approved for different populations, and require different daily habits. Whether the pill is the right choice for you depends on your diagnosis, your goals, what else you're taking, and how your mornings are structured.

Bring the specifics to your clinician — and now you have enough to make that a focused conversation.

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

• Novo Nordisk / PRNewswire — Ozempic pill for T2DM (May 1, 2026): https://www.prnewswire.com/news-releases/novo-nordisks-ozempic-pill-the-only-fda-approved-oral-peptide-glp-1-medication-for-adults-with-type-2-diabetes-soon-to-be-available-in-the-us-302760106.html
• FDA Full Prescribing Information — Wegovy (semaglutide) tablets, revised 12/2025: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf
• Novo Nordisk / PRNewswire — Wegovy pill FDA approval (December 22, 2025): https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-302648344.html
• OASIS 4 trial (NCT05564117), Phase III — NEJM, September 2025
• Ozempic tablet prescribing information: https://www.novo-pi.com/ozempictablets.pdf"